Feb 2, 2023 · In a US-based phase 2 trial, ziltivekimab, a fully human monoclonal antibody targeting the interleukin-6 ligand, significantly reduced biomarkers of inflammation compared with placebo in patients at high atherosclerotic risk.

Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). This is known as the study medicine. Which treatment participants get is decided by chance. Participants chance of getting ziltivekimab or placebo is the same.

May 29, 2021 · The RESCUE trial data provides the first evidence that inhibition of IL-6 with the novel monoclonal ligand antibody ziltivekimab reduces in a dose-dependent manner multiple inflammatory and thrombotic biomarkers relevant for atherosclerosis, in a critical population of patients with chronic kidney disease and high cardiovascular risk who have ...

Aug 5, 2021 · With plans to initiate worldwide enrolment in late 2021, ZEUS will compare ziltivekimab to placebo among 6200 patients with Stages 3–4 CKD and elevated hsCRP to formally test whether reducing circulating IL-6 reduces cardiovascular event rates.

We report the design of the ZEUS trial (NCT05021835) investigating the effects of subcutaneous ziltivekimab 15 mg monthly, compared with placebo, in participants with CKD, ASCVD, and elevated hsCRP levels. ZEUS is a randomized, double-blind, parallel-group CV outcomes trial.

Apr 6, 2022 · Data derived from the CANTOS trial, in which canakinumab was assessed to treat patients with atherosclerotic disease and kidney dysfunction, has opened a new lane of assessment into patients with the comorbid disease.

Results of this post hoc analysis of the RESCUE trial suggest that ziltivekimab, which lowered hsCRP level in RESCUE, was associated with reductions in the NLR, a parameter readily available from routine blood cell counts.

The ZEUS study will see if ziltivekimab can reduce the risk of having cardiovascular events (for example heart attack and stroke). The term cardiovascular disease refers to several conditions that affect your heart and blood vessels.

ZEUS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation. Principal Investigator: Naveed N. Masani. Other Investigators: James Drakakis, Candace Grant.

Sep 28, 2021 · From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction? Cardiovasc Res. 2021 Sep 28;117 (11):e138-e140. doi: 10.1093/cvr/cvab231.